Costs of olanzapine treatment compared with haloperidol for schizophrenia: Results from a randomized clinical trial

被引：4
|
作者：
Hamilton, SH [1 ]
Revicki, DA [1 ]
Genduso, LA [1 ]
Tollefson, GD [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
SCHIZOPHRENIA RESEARCH | 1998年 / 29卷 / 1-2期
关键词：
D O I：
10.1016/S0920-9964(97)88678-1
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [1] Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia - Results from a randomised clinical trial
    Hamilton, SH
    Revicki, DA
    Edgell, ET
    Genduso, LA
    Genduso, LA
    Tollefson, G
    PHARMACOECONOMICS, 1999, 15 (05) : 469 - 480
  • [2] Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: Results from a US randomized controlled trial
    Namjoshi, M
    Young, CA
    Huang, L
    Edgell, E
    Breier, A
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 296 - 296
  • [3] Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia - A randomized controlled trial
    Rosenheck, R
    Perlick, D
    Bingham, S
    Liu-Mares, W
    Collins, J
    Warren, S
    Leslie, D
    Allan, E
    Campbell, EC
    Caroff, S
    Corwin, J
    Davis, L
    Douyon, R
    Dunn, L
    Evans, D
    Frecska, E
    Grabowski, J
    Graeber, D
    Herz, L
    Kwon, K
    Lawson, W
    Mena, F
    Sheikh, J
    Smelson, D
    Smith-Gamble, V
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (20): : 2693 - 2702
  • [4] Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a US randomized controlled trial
    Namjoshi, M
    Young, C
    Huang, L
    Edgell, ET
    Breier, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S315 - S315
  • [5] Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
    Dennis A. Revicki
    Laura A. Genduso
    Susan H. Hamilton
    Dara Ganoczy
    Charles M. Beasley
    Quality of Life Research, 1999, 8 : 417 - 426
  • [6] Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
    Revicki, DA
    Genduso, LA
    Hamilton, SH
    Ganoczy, D
    Beasley, CM
    QUALITY OF LIFE RESEARCH, 1999, 8 (05) : 417 - 426
  • [7] Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and other psychotic disorders: Results of an international clinical trial
    Revicki, D
    Haley, J
    Hamilton, S
    Genduso, L
    Beasley, C
    QUALITY OF LIFE RESEARCH, 1997, 6 (7-8) : 315 - 315
  • [8] Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for SchizophreniaResults From a Randomised Clinical Trial
    Susan H. Hamilton
    Dennis A. Revicki
    Eric T. Edgell
    Laura A. Genduso
    Gary Tollefson
    PharmacoEconomics, 1999, 15 : 469 - 480
  • [9] COSTS AND EFFECTS OF ILOPERIDONE COMPARED WITH OLANZAPINE AND HALOPERIDOL IN PATIENTS WITH ACUTE SCHIZOPHRENIA: RESULTS FROM A COST-EFFECTIVENESS MARKOV MODEL
    Elsaid, K. A.
    Angelini, M.
    VALUE IN HEALTH, 2010, 13 (03) : A113 - A113
  • [10] Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
    Tollefson, GD
    Beasley, CM
    Tran, PV
    Street, JS
    Krueger, JA
    Tamura, RN
    Graffeo, KA
    Thieme, ME
    AMERICAN JOURNAL OF PSYCHIATRY, 1997, 154 (04): : 457 - 465
12345